DKSH and Merdury Biopharmaceutical Corporation have entered into a partnership to supply the latter’s Metformin to the Vietnamese market. — Photo courtesy of DKSH

DKSH, a leading market expansion services provider, has signed a memorandum of understanding with Merdury Biopharmaceutical Corporation to bring Metformin, a rapid-acting treatment for type 2 diabetes, to Việt Nam.

DKSH will support Merdury with procedures to access the market. The product will be distributed by local distribution partners after importation.

Founded in July 2019, Merdury focuses on the development of drugs for unmet medical needs. With its proprietary StackDose platform, which is developed based on a 3D powder printing technology and process, and a unique drug binding formula, Merdury develops new tablet dosage forms with controlled time dissolution and precise site absorption.

Its drugs also improve the bioavailability of active pharmaceutical ingredients (APIs) to optimise their effects, thereby reducing the dosage of drugs used and thus reducing side effects.

Edward Lin, chairman of Merdury Biopharmaceutical, said at the signing ceremony: “Việt Nam is one of our key markets as we aim to expand our presence outside Taiwan with our advanced diabetes treatment. We highly value DKSH’s expertise and its capillary network of partners in Việt Nam, which we believe, is strategic to our future growth in this exciting market.”

Phillip Wray, general director, DKSH Pharma Vietnam, said: “This MoU marks the first important step on our shared journey of bringing rapid-acting treatment for type 2 diabetes to the Vietnamese market. We are excited to be Merdury’s trusted partner, and we are thrilled that diabetes patients in Việt Nam will soon have better access to more treatment options.” — VNS